On December 25, the State Drug Administration approved the clinical trial application for the freeze-dried herpes zoster virus mRNA vaccine developed by Beijing Kexing Zhongwei Biotechnology Co., Ltd., a subsidiary of Sinovac Kexing. The vaccine can stimulate the body to develop immunity against the shingles virus and is used to prevent shingles in people aged 40 and above.

Zhitongcaijing · 12/26/2024 06:33
On December 25, the State Drug Administration approved the clinical trial application for the freeze-dried herpes zoster virus mRNA vaccine developed by Beijing Kexing Zhongwei Biotechnology Co., Ltd., a subsidiary of Sinovac Kexing. The vaccine can stimulate the body to develop immunity against the shingles virus and is used to prevent shingles in people aged 40 and above.